Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TRML Stock Forecast 2025-2026
$18.18
Current Price
$505.55M
Market Cap
Buy 11
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TRML Price Targets
+285.0%
To High Target of $70.00
+210.8%
To Median Target of $56.50
+92.5%
To Low Target of $35.00
TRML Price Momentum
-8.6%
1 Week Change
+9.3%
1 Month Change
+16.9%
1 Year Change
-10.4%
Year-to-Date Change
-39.0%
From 52W High of $29.79
+57.3%
From 52W Low of $11.56
📊 TOP ANALYST CALLS
Did TRML Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Tourmaline Bio is one of their latest high-conviction picks.
Latest TRML Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, TRML has a bullish consensus with a median price target of $56.50 (ranging from $35.00 to $70.00). Currently trading at $18.18, the median forecast implies a 210.8% upside. This outlook is supported by 11 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Daniil Gataulin at Chardan Capital, projecting a 285.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TRML Analyst Ratings
11
Buy
0
Hold
0
Sell
TRML Price Target Range
Low
$35.00
Average
$56.50
High
$70.00
Current: $18.18
Latest TRML Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TRML.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 5, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $50.00 |
| May 5, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $70.00 |
| Apr 23, 2025 | Chardan Capital | Daniil Gataulin | Buy | Initiates | $70.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $50.00 |
| Mar 14, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $43.00 |
| Mar 6, 2025 | Wedbush | Laura Chico | Outperform | Initiates | $42.00 |
| Feb 24, 2025 | LifeSci Capital | Jimmy Shan | Outperform | Initiates | $58.00 |
| Dec 11, 2024 | Guggenheim | Yatin Suneja | Buy | Reiterates | $0.00 |
| Dec 11, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $49.00 |
| Dec 11, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $25.00 |
| Dec 6, 2024 | BMO Capital | Etzer Darout | Outperform | Initiates | $50.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $49.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $48.00 |
| May 14, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $48.00 |
| Mar 25, 2024 | Truist Securities | Robyn Karnauskas | Buy | Reiterates | $74.00 |
| Mar 20, 2024 | Jefferies | Roger Song | Buy | Maintains | $72.00 |
| Mar 20, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $48.00 |
| Dec 15, 2023 | Jefferies | Roger Song | Buy | Initiates | $41.00 |
| Nov 17, 2023 | Truist Securities | Robyn Karnauskas | Buy | Initiates | $43.00 |
| Oct 31, 2023 | Guggenheim | Yatin Suneja | Buy | Initiates | $50.00 |
Tourmaline Bio Inc. (TRML) Competitors
The following stocks are similar to Tourmaline Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Tourmaline Bio Inc. (TRML) Financial Data
Tourmaline Bio Inc. has a market capitalization of $505.55M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -26.1%.
Valuation Metrics
Market Cap
$505.55M
Enterprise Value
$238.20M
P/E Ratio
0.0x
PEG Ratio
-5.2x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+53.4%
Current Ratio
33.9x
Debt/Equity
0.1x
ROE
-26.1%
ROA
-19.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Tourmaline Bio Inc. (TRML) Business Model
About Tourmaline Bio Inc.
What They Do
Develops therapies for immune-inflammatory diseases.
Business Model
Tourmaline Bio Inc. operates by advancing its pipeline of innovative therapeutic candidates through clinical trials, focusing on conditions with unmet medical needs. The company generates revenue by commercializing these therapies once they receive regulatory approval and are brought to market.
Additional Information
The company emphasizes research and employs advanced scientific methodologies, positioning itself as a leader in the biotechnology sector. Its work contributes to the shift towards biologics and precision therapies, potentially impacting the pharmaceutical industry and improving treatment options for patients.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
74
CEO
Dr. Sandeep C. Kulkarni M.D.
Country
United States
IPO Year
2023
Website
www.tourmalinebio.comTourmaline Bio Inc. (TRML) Latest News & Analysis
Latest News
Quick Summary
Tourmaline Bio, Inc. (NASDAQ: TRML) will host a conference call on May 20, 2025, to present topline results from its Phase 2 TRANQUILITY trial on pacibekitug for chronic kidney disease.
Why It Matters
Tourmaline Bio's conference call on Phase 2 trial results could influence stock performance, reflecting investor sentiment on its drug's potential and market viability in treating chronic conditions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pacibekitug demonstrated significant hs-CRP reduction in CKD patients, supporting its advancement to phase 3 trials for ASCVD, with a market potential of $30.6 billion by 2035.
Why It Matters
Pacibekitug's promising phase 2 results in reducing hs-CRP for CKD patients enhance its potential market for ASCVD, forecasting significant revenue growth in a $30.6 billion sector.
Source: Seeking Alpha
Market Sentiment:
Positive
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
1 month ago
Quick Summary
Tourmaline Bio expects to report topline data from its Phase 2 TRANQUILITY trial in Q2 2025. The company has $275.3M in cash, providing a runway into H2 2027.
Why It Matters
The upcoming TRANQUILITY trial data in 2025 could significantly impact Tourmaline's stock, indicating potential breakthroughs in treating cardiovascular inflammation, while substantial cash reserves ensure operational stability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
3 months ago
Quick Summary
The Phase 2 TRANQUILITY trial has enrolled 143 participants and is set to report topline data in Q2 2025. The Cardiovascular Scientific Advisory Board has added notable experts.
Why It Matters
The over-enrollment in the TRANQUILITY trial could enhance data robustness, while the strengthened advisory board suggests a focus on cardiovascular research, potentially boosting investor confidence in future outcomes.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tourmaline Bio, Inc. (NASDAQ: TRML) announced CEO Sandeep Kulkarni will participate in an upcoming investor conference, focusing on its late-stage clinical development in immune and inflammatory diseases.
Why It Matters
Sandeep Kulkarni's participation in the investor conference could signal confidence in Tourmaline's progress, potentially influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
5 months ago
Quick Summary
Tourmaline Bio, Inc. (NASDAQ: TRML) has appointed Dr. Paul M. Ridker to its Cardiovascular Scientific Advisory Board, enhancing its expertise in developing treatments for immune and inflammatory diseases.
Why It Matters
Tourmaline's appointment of a prominent expert to its advisory board enhances its credibility and potential for innovation, likely boosting investor confidence and interest in its pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About TRML Stock
What is Tourmaline Bio Inc.'s (TRML) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, Tourmaline Bio Inc. (TRML) has a median price target of $56.50. The highest price target is $70.00 and the lowest is $35.00.
Is TRML stock a good investment in 2025?
According to current analyst ratings, TRML has 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TRML stock?
Wall Street analysts predict TRML stock could reach $56.50 in the next 12 months. This represents a 210.8% increase from the current price of $18.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tourmaline Bio Inc.'s business model?
Tourmaline Bio Inc. operates by advancing its pipeline of innovative therapeutic candidates through clinical trials, focusing on conditions with unmet medical needs. The company generates revenue by commercializing these therapies once they receive regulatory approval and are brought to market.
What is the highest forecasted price for TRML Tourmaline Bio Inc.?
The highest price target for TRML is $70.00 from Daniil Gataulin at Chardan Capital, which represents a 285.0% increase from the current price of $18.18.
What is the lowest forecasted price for TRML Tourmaline Bio Inc.?
The lowest price target for TRML is $35.00 from at , which represents a 92.5% increase from the current price of $18.18.
What is the overall TRML consensus from analysts for Tourmaline Bio Inc.?
The overall analyst consensus for TRML is bullish. Out of 14 Wall Street analysts, 11 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $56.50.
How accurate are TRML stock price projections?
Stock price projections, including those for Tourmaline Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 18, 2025 5:38 PM UTC